1606-01-5

Basic information

• Product Name: DIETHYLGLYCINE HYDROCHLORIDE
• Synonyms: DIETHYLGLYCINE HYDROCHLORIDE;Diethylamino-acetic acid hydrochloride;Diethylglycine hydrochloride ,98.5%;glycine, N,N-diethyl-;2-(diethylamino)acetic acid hydrochloride;2-(diethylamino)ethanoic acid;N,N-diethylglycine(SALTDATA: HCl);N,N-DiethylaMinoacetic acid
• CAS NO: 1606-01-5
• Molecular Formula: C₆H₁₃NO₂
• Molecular Weight: 167.63
• EINECS: 216-520-8
• Mol File: 1606-01-5.mol

Chemical Properties

• Melting Point: 126-130 °C
• Boiling Point: 203.2 °C at 760 mmHg
• Flash Point: 76.7 °C
• Appearance: /
• Density: 1.013 g/cm³
• Vapor Pressure: 0.116mmHg at 25°C
• PKA: 2.34±0.10(Predicted)
• CAS DataBase Reference: DIETHYLGLYCINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DIETHYLGLYCINE HYDROCHLORIDE(1606-01-5)
• EPA Substance Registry System: DIETHYLGLYCINE HYDROCHLORIDE(1606-01-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1606-01-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DIETHYLGLYCINE HYDROCHLORIDE is used as a drug development compound for the treatment of neurological disorders, leveraging its potential to address specific conditions in this therapeutic area.
Used in Chemical Synthesis:
DIETHYLGLYCINE HYDROCHLORIDE is used as a reagent in chemical synthesis processes, contributing to the creation of novel organic compounds.
Used in Analytical Chemistry:
DIETHYLGLYCINE HYDROCHLORIDE is used as a chelating agent in analytical chemistry, facilitating the analysis and detection of various chemical substances.
Used in Drug Formulation:
DIETHYLGLYCINE HYDROCHLORIDE is used as a solubility and bioavailability enhancer in drug formulations, improving the performance of poorly water-soluble drugs.

InChI:InChI=1/C6H13NO2.ClH/c1-3-7(4-2)5-6(8)9;/h3-5H2,1-2H3,(H,8,9);1H

Upstream product

• 2644-21-5 ethyl N,N-diethylglycinate 
• 75-07-0 acetaldehyde 
• 56-40-6 glycine 
• 79-08-3 bromoacetic acid 
• 109-89-7 diethylamine 
• 79-11-8 chloroacetic acid 
• 64-67-5 diethyl sulfate 
• 592-41-6 1-hexene 
• 816-43-3 lithium diethylamide 
• 19326-51-3 chloroacetic acid lithium salt 
• 64916-53-6 bromoacetic acid lithium salt 
• 64-17-5 ethanol 
• 5426-55-1 N,N-diethylglycine sodium salt 

Downstream Products

• 943316-05-0 [5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2,4-ditert-butyl-phenyl] 2-diethylaminoacetate 
• 943316-00-5 [4-(4-ethoxyphenyl)-5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2-tert-butyl-phenyl] 2-diethylaminoacetate hydrochloride 
• 1236808-99-3 3'-N-demethyl-4-O-(2-diethylaminoethanoyl)-2'-O-3'-N-di-{[(phenylmethyl)oxy]carbonyl}-6-O-methyl-9a-aza-9a-homoerythromycin A 
• 1253960-43-8 1-(4-(4-amino-5-(4-(3,4-dichlorophenoxy)-3-methoxyphenyl)-6-(3-(pyrrolidin-1-yl)propyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-(diethylamino)ethanone 
• 1262439-76-8 2-(diethylamino)-N-((3-(4-methoxyphenyl)4,5-dihydroisoxazol-5-yl)methyl)ethanamide 
• 1262439-77-9 (3-(4-methoxyphenyl)isoxazol-5-yl)methyl (diethylamino)acetate 
• 1262439-78-0 2-(diethylamino)-N-(3-(4-methoxyphenyl)isoxazol-5-yl)ethanethioamide 
• 478049-40-0 2-(diethylamino)-N-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-24-6 2-(diethylamino)-N-((3-(3-methoxyphenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-25-7 2-(diethylamino)-N-((3-(4-hydroxyphenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-26-8 2-(diethylamino)-N-((3-(4-nitrophenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-27-9 2-(diethylamino)-N-((3-(3-nitrophenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-28-0 2-(diethylamino)-N-((3-(4-(trifluoromethyl)phenyl)isoxazol-5-yl)methyl)ethanamide 
• 1262439-29-1 N-(3-(3,4-dimethoxyphenyl)isoxazol-5-yl)methyl-2-(diethylamino)ethanamide 

Relevant articles and documents

TRPV1 agonist, preparation method and application thereof

The present invention relates to a compound represented by a formula I, a stereoisomer, a tautomer, a solvate, a polymorph or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a preparation method and a medical use of the compound, wherein the structure of the formula I is shown in the specification.

Nitrogen-containing cyclic compounds as iminium ion sources for selected reaction monitoring detection of derivatized analytes

Liquid chromatography–tandem mass spectrometry is one of the most sensitive tools for determination of trace amounts of analytes in metabolomics and proteomics. The highest sensitivity is achieved in selected reaction monitoring detection, which involves fragmentation of the molecular ion between two levels of mass selection. However, fragmentation of some compounds is complicated. Detection sensitivity of such analytes may be increased by derivatizing them with a specific moiety fragmentation of which results in product ion of high abundance. In this work, we reveal the influence of iminium ions' structures on their stability by comparing six nitrogen-containing cyclic compounds as derivatization reagents for tandem mass spectrometric analysis of amino group-containing analyte. Commercially available starting materials (piperidine, 2,6-dimethylpiperidine, 1-methylpiperazine, morpholine, pyrrolidine and 1-cyanomethyl-3-methylimidazolium ionic liquid) were used for the synthesis of corresponding carboxylic acids which were further used for derivatization of the model analyte tryptamine. Liquid chromatographic–mass spectrometric analysis of differently derivatized tryptamine was performed for the evaluation of release and stability of corresponding iminium ions under collision-induced dissociation conditions. As a result, morpholine moiety was shown being the most promising iminium ion source among tested compounds. Possible sub-fragmentation pathways of investigated iminium ions were discussed, and the structures of secondary product ions were proposed.

Method and using tracer charged ion channel

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

N-ALKYLATED AMINO ACIDS AND OLIGOPEPTIDES, USES THEREOF AND METHODS FOR PROVIDING THEM.

The invention relates to the synthesis of amphiphilic amino acid derivatives, in particular to a method for the N-alkylation of an unprotected amino acid or the N-terminus of an oligopeptide substrate, comprising reacting said unprotected amino acid or oligopeptide substrate with an alcohol, e.g. a fatty alcohol, in the presence of a homogeneous transition metal catalyst.

Reactions of α-carbanions of lithium acylates with N,N-diethyl-N-chloro- and N,N-diethyl-N-bromoamines

The interaction of α-carbanions of lithium acylates (prepared via metalation of acetic, butyric, or isobutyric acid with lithium diisopropylamide in tetrahydrofuran under argon atmosphere) with N,N-diethyl-N-chloro- or N,N-diethyl-N-bromoamine has resulte

Anti-Infammatory Macrolide

The compound 3′-N-demethyl-4″-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment of neutrophil dominated inflammatory diseases, and methods for its preparation.

HIGHLY CONCENTRATED AQUEOUS SOLUTIONS OF N,N-DIALKYLGLYCINES AND PROCESS FOR PREPARATION THEREOF

An aqueous high-concentration solution of N,N-dialkylglycine, economical, easy to handle, and useful for subsequent organic chemical reactions, is provided. Also is provided a process for production thereof. The aqueous high-concentration solution of N,N-dialkylglycine which contains the N,N-dialkylglycine at a concentration of 30-80 % by mass, and a metal-mineral acid salt at a content of 0.3-3 % by mass can be produced industrially from an aqueous N,N-dialkylglycine alkali metal salt as the source material by the steps of(i) neutralizing an aqueous solution of an N,N-dialkylglycine alkali metal salt with a mineral acid,(ii) condensing the obtained aqueous solution by removal of water, and(iii) separating by solid-liquid separation the deposited alkali metal-mineral acid salt from the resulting slurry of the aqueous N,N-dialkylglycine solution and the alkali metal-mineral acid salt.

Efficient and Highly Selective Copper(II) Transport across a Bulk Liquid Chloroform Membrane Mediated by Lipophilic Dipeptides

Several structurally simple N-monoalkylated and -dialkylated dipeptides made of α-amino acids Gly, Phe, and Leu, 1-11, were synthesized and investigated as carriers for the transport of Cu(II), Zn(II), and Ni(II) from an aqueous pH = 5.6 buffer source to a 0.1 M HCl receiving phase across a bulk chloroform membrane. The proton-driven translocation was followed during the process by analyzing the metal ion concentrations in the three phases. The transport efficiency depends on the ease of formation of a neutral complex with Cu(II) (the peptide group and carboxylic acid being deprotonated) at the source-chloroform interface and on that of its disruption by protonation at the receiving phase: the carrier's lipophilicity favors the metal ion uptake and not the release. By modulating the length of the N-alkyl chains and the hydrophobicity of the dipeptide moiety, a quite remarkable transport efficiency was observed for Cu(II), in most cases superior to that of the industrial extractant Kelex 100. Moreover, using L,L- and L,D-N-octyl-PheLeu as carriers, remarkable diastereomeric effects were observed in the rate of uptake and release of Cu(II) ion although the differences mutually compensate in the overall transport rate. Under the conditions used the carriers are much less effective in the translocation of Zn(II) and Ni(II) and their transport efficiency drops dramatically in the presence of Cu(II), the latter being favored by factors of 1.2 × 103 and > 104, respectively. Such very high selectivities depend on the fact that only Cu(II) among other transition metal ions can form neutral complexes at the pH value of the source phase.

Novel pharmacological compounds

Novel compounds of the formula STR1 pharmaceutical compositions containing such compounds as active ingredient with gastric and inhibiting effects.